Monopar Therapeutics Inc.

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment of cancer. Its lead product candidate is ALXN1840, a late-stage, once-daily oral medicine for Wilson disease, which it develops under a license agreement with Alexion. The company also has a proprietary platform based on MNPR-101, a humanized monoclonal antibody targeting the urokinase plasminogen activator receptor (uPAR) expressed on advanced solid tumors. MNPR-101 is conjugated with different radioisotopes to create both imaging and therapeutic agents: MNPR-101-Zr (a phase 1 imaging agent) and MNPR-101-Lu (a phase 1a radiotherapeutic). Additionally, Monopar collaborates with NorthStar on radio-immuno-therapeutics for severe COVID-19.

Monopar Therapeutics Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol MNPR. Its shares are traded in US Dollars (USD), reflecting its primary listing in the United States. The company is headquartered in Wilmette, Illinois, and its operations are based in the US, so the USD is the natural currency for its financial reporting and stock trading.

Monopar Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing novel therapies for cancer and other diseases. Biotechnology companies like Monopar typically engage in drug discovery, preclinical studies, and clinical trials to bring new treatments to market. The company's work involves advanced technologies such as monoclonal antibodies and radioisotope conjugates for targeted cancer therapy.

Monopar Therapeutics is headquartered in Wilmette, Illinois, United States. The company primarily serves the US market, as indicated by its focus on US-based clinical trials and regulatory pathways. Its pipeline includes drugs for cancer and Wilson disease, with clinical trials conducted in the US. While the company may eventually seek global markets, its current operations and collaborations (e.g., with NorthStar and Alexion) are centered in the United States.

Monopar Therapeutics' pipeline includes several key assets. ALXN1840 is a late-stage, once-daily oral medicine for Wilson disease, licensed from Alexion. The MNPR-101 platform includes MNPR-101-Zr, a phase 1 imaging agent that uses zirconium-89 for PET imaging of uPAR-expressing tumors, and MNPR-101-Lu, a phase 1a radiotherapeutic conjugated with actinium-225 for targeted treatment. The company also has a collaboration with NorthStar to develop radio-immuno-therapeutics for severe COVID-19. Additionally, Monopar works with Excel Diagnostics and Nuclear Oncology Center to support clinical development of its imaging and therapeutic agents.